INTRODUCTION
Malaria is known to be the most deadly parasitic infection in the world. Indeed, malaria is responsible for many deaths every year, cripples economic growth especially in Africa and perpetuates the vicious circle of poverty [1] . In spite of considerable progress toward the control and fight against malaria, it still represents a public health concern in many areas, particularly in sub-Saharan Africa. Unfortunately, between 2015 and 2016, mortality rates stalled in the WHO regions of South-East Asia, the Western Pacific and Africa, and increased in the Eastern Mediterranean and America. That reconfirms we are of course to meet two critical 2020 milestones of the WHO Global Technical Strategy for Malaria 2016-2030: reducing case incidence and death rates by at least 40% from 2015 levels [2] .
In Burkina Faso, malaria is endemic and constitutes the main cause of consultation, hospitalization and mortality in health facilities. Children under 5 years and pregnant women pay the highest tribute for this disease each year [3] . In 2016, this disease led to 45% of consultation, 45.6% of hospitalization and 25.2% of deaths [4] . Unfortunately, despite the considerable progress made over the last decade in search of a malaria vaccine, there is still no effective vaccine available ready against malaria. The most advanced RTS, S vaccine is still at an implementation phase in Ghana, Kenya and Malawi [5] . The current struggle against malaria is based on vector control. The main way of preventing and reducing the transmission of malaria; the prevention and treatment with specific and effective antimalarial drugs. However, one of the major concern in malaria treatment (curative or prophylactic) is currently the progression of resistance of Plasmodium falciparum to antimalarials, in general, threatening the Artemisinin-based combination therapy (ACTs) considered to be more effective against malaria Plasmodium falciparum [6] . Indeed, the emergence of a strain of malaria that is resistant to artemisinin-based combination therapy (ACT) in Southeast Asia (the currently recommended first-line treatment for malaria) is a concern because it threatens to stop or reduce the progress that's been made against malariacausing parasites in recent years [7, 8] .
This resistance is characterized by a decrease in the sensitivity of ACTs observed in Southeast Asia. No alternative therapeutic solution is currently available. Moreover, it was shown from the analysis of common mutant resistance genes as Pfcrt (Plasmodium falciparum chloroquine resistance transporter) and Pfdhfr (Plasmodium falciparum dihydrofolate reductase) a genetic origin links with the parasite from the Thailand-Cambodia border [9, 10] . However, up to date, there is no clear evidence that artemisinin resistance parasites have reached Africa yet [11] . In that context of the damage caused by resistance, it is, therefore, necessary to continue to carry out studies that will assuredly make it possible to evaluate drug resistance for monitoring resistance to current antimalarials drugs. Thus, several studies have been conducted around the world in general and particularly in Africa, where several mutations associated with resistance to antimalarials, including the Pfcrt76T gene mutation in the parasite, resistance to chloroquine and therapeutic failures have been identified [12] . These phenomena of resistance to the previous antimalarials led several countries to change their malaria treatment policy, particularly with the introduction of artemisinin-based combination therapies, further to consultation with the World Health Organization [13] . However, in Burkina Faso, ACTs are known to be effective on Pfcrt76T parasite and have been used in the treatment of malaria since 2005. Unfortunately, to our knowledge, there are no molecular markers which demonstrated any correlation with resistance to the used ACTs. Therefore, it is still recommended to continue monitoring the prevalence of existing known molecular markers such as Pfcrt, as a signal of the evolution of parasite resistant population. The present study was initiated in the framework of the characterization of the Pfcrt76T mutation associated with antimalarial drug resistance in the treatment of Plasmodium falciparum malaria in Banfora and Saponé in the western and central part of Burkina Faso, more than eight years after the introduction of ACTs.
MATERIAL AND METHODS

Study Area
The study was conducted in two different epidemiological settings (Banfora and Saponé) from September 2012 to September 2013 as part of two antimalarial drugs clinical studies.
The first study area, Banfora Health District area, in the province of Comoé, is located at 441 km west of Ouagadougou, the capital of Burkina Faso. Malaria transmission is markedly seasonal and intense during the rainy season (May -November).
The cumulative annual entomological inoculation rate varies from 55 to 400 infective bites/person/year. Plasmodium falciparum is the main parasite present in more than 90% of infections.
The second study area was the Saponé Health district, located in -the province of Bazéga, a rural area at 50 km south-west of Ouagadougou where malaria is mesoendemic. Malaria transmission in this district is permanent with a peak during the intense and seasonal rainy season from June to November.
Study Participants and Samples Collection
About 181 participants, from both male and female, aged from 6 months and above were included in this study. For each patient included in the study, blood samples were taken from the finger prick to prepare blood spots on filter paper and blood smears for malaria diagnosis. The filter paper spots were each kept in a plastic bag containing silica gel to keep the medium dry, then inserted into an envelope and transported to the Molecular Biology Laboratory at CNRFP (Centre National de Recherche et de Formation sur le Paludisme ) waiting for molecular analysis of Pfcrt76T mutation.
As selected from the clinical studies, the only participant having a complete demographic data (age, sex) and analyzable samples (blood smears for microscopy, filter paper for parasite genotyping) were included in the study for subsequent molecular analysis.
Asexual Plasmodium falciparum Parasites Density
Thick and thin blood smears were used for microscopic diagnosis of a parasite count in the parasitology laboratory at CNRFP. Thick and thin blood smears were stained with Giemsa. The number of asexual Plasmodium falciparum parasites was estimated against 200 leucocytes and parasite density was calculated assuming a mean of 8000 leucocytes per µl. A sample was declared negative after examining 200 thick film fields without observing any asexual parasites.
DNA Extraction of Plasmodium falciparum
DNA of Plasmodium falciparum was extracted from the blood spots using DNA extraction kits (Qiagen ® ) according to the manufacturer's instructions. Briefly, the blood was first dissolved in a solution and the red blood cells burst by osmotic shock by mixing it with a hypotonic solution (ATL buffer). These were then introduced into the resulting mixture, a detergent (buffer AL) to destroy Plasmodium membranes and proteinase K to digest proteins associated with DNA. The parasite DNA was precipitated with ethyl alcohol (100%) and retained in the extraction columns followed by a double washing successively with the solutions (buffer AW1 and AW2). Finally, the eluent (buffer AE) is used to collect the DNA of Plasmodium falciparum in final tubes. The DNA was stored at -20°C until used. 
DNA of Plasmodium falciparum was extracted from the blood spots using DNA extraction kits (Qiagen ® ) according to the manufacturer's instructions. Briefly, the blood was first dissolved in a solution and the red blood cells burst by osmotic shock by mixing it with a hypotonic solution (ATL buffer). These were then introduced into the resulting mixture, a detergent (buffer AL) to destroy Plasmodium membranes and proteinase K to digest proteins associated with DNA. The parasite DNA was precipitated with ethyl alcohol (100%) and retained in the extraction columns followed by a double washing successively with the solutions (buffer AW1 and AW2). Finally, the eluent (buffer AE) is used to collect the DNA of Plasmodium falciparum in final tubes. The DNA was stored at -20°C until used. The tubes were then placed into the thermocycler for digestion at 50°C for 6 hours followed by agarose (2%) gel electrophoresis.
Visualization of Pfcrt gene Mutations by Agarose Gel Photography
After the electrophoresis, the mutations were then visualized by a device under UV.
A successful reaction is reflected by the presence of specific expected sized bands. The expected band sizes were given concerning the molecular marker and confirmed by the positive control. The sample containing a single 134 bp band Pfcrt 76T) is considered as a mutant while the sample with both 100 bp and 34 bp (Pfcrt 76 K) bands is considered as a wild type. Mixed infections samples are represented with 134 bp, 100 bp and 34 bp with the presence of both Pfcrt 76T and Pfcrt 76 K).
Two samples out of 181 gave negative PCR of 1.10%.
Statistical Analyses
The data were double entered into a database using an Access 2007 programme and analyzed using the software Stata IC version 13. Pearson χ2 tests and Fisher's exact test were used for comparison of proportions. P-value ≥0.05 was used as the threshold significance for the different statistical tests.
RESULTS
Socio-demographic Characteristics
The study population consisted of 50.83% (92/181) of female and 48.9% (89/182) of male both aged from 1 to 59 years with a sex ratio of 1.03 (F / M). The mean age was estimated at 17.57 ± 16.2 years. The Children under 5 years old accounted for 31, 50% of the study population while participant more and those aged between 5 and 12 years while those of older age > 15 years accounted for 51.93% of the study population (Table1).
Prevalence of the Pfcrt 76 Alleles in the Study Population
The frequency of alleles carriage was estimated at 33.70%, 57.40% and 7.80% respectively for the mutant allele (pfcrt76T), the wild type allele (pfcrt76K) and mixed alleles or heterozygous type (Pfcrt76T and Pfcrt76K) in the study population ( Fig. 1 ).
Prevalence of pfcrt76T Mutation According to Study Areas
The distribution of both mutant and wild type carriers was analyzed according to the two study sites ( 
Prevalence of Mutant Alleles According to Age
There was no statistically significant difference when comparing the prevalence between Pfcrt76T (mutant) and Pfcrt76K (wild) as a function of age (p = 0.08) (Fig. 2) . However, the prevalence of the wild type Pfcrt 76K alleles carriage was statically higher than the mutant ones in patients for more than 10 years (p<0.05).
Prevalence of Different Alleles of Pfcrt According to Parasitaemia
The prevalence of different Pfcrt alleles was analyzed as a function of parasite density considering three population groups based on the clinical malaria definition from several clinical studies (Table 3) didn't showed any statistically significant difference when comparing the frequencies of the mutant (p = 0, 71), the wild type (p = 0.60) as well as Heterozygous (p = 0.56) according to the different parasite density ranges.
DISCUSSION
The Prevalence of the pfcrt76T Mutation in the Study Population
The Pfcrt alleles distribution assessed in our study in both study areas Banfora and Saponé Health District area showed a reduced rate compared to the previous studies carried out in Burkina Faso in the last few years. Indeed, with an overall prevalence of 34% in the study population, the mutant allele Pfcrt 76T presents a reduction compared to the 61.4%, 65%, obtained 
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DISCUSSION
The Prevalence of the pfcrt76T Mutation in the Study Population
The Pfcrt alleles distribution assessed in our study in both study areas Banfora and Saponé Health District area showed a reduced rate compared to the previous studies carried out in Burkina Faso in the last few years. Indeed, with an overall prevalence of 34% in the study population, the mutant allele Pfcrt 76T presents a reduction compared to the 61.4%, 65%, obtained [14] and 2005 [15] in Bobo Dioulasso respectively. The findings of this study were lower than the prevalence of 48.8% and 50% obtained in 2008 by MAHAMAT et al. [16] in Gourcy and Dandé located at the North and western part of Burkina Faso respectively. The overall significance of this study indicated a clear reduction of the chloroquine resistance parasite since the introduction of the ACTs in 2005 in Burkina Faso. This conforms with the results obtained by Some et al. in 2016 as well as [17] . This re-affirmed the efficacy of the ACTs on the chloroquine-resistant parasite as described previously. Looking at this decrease in the prevalence of the Pfcrt76T mutation over the years, the reduction to the zero rates of the Pfcrt76T resistant allele in the long term would be a possibility, as observed in Malawi [18] . However, the proportion of the circulating resistant Pfcrt 76T alleles is timely and geographically varying in malaria-endemic countries as confirmed by different results in Niger in 2006 (50%) and Malaysia in 2012 (52%) and 2016 (97.7%) [19] .
During the PCR analyses, negative results for PCR were obtained (without bands of genes). This could be explained by a very small amount of parasitic DNA in these samples as we did not get the DNA quantified before amplifying. Indeed, a minimum amount of DNA is needed to amplify it. An additional possible explanation may be related to the occurrence of reading errors of slides declaring a patient positive while it is negative.
Prevalence of pfcrt76T According to Age
In this study, there was no statistically significant difference when comparing the prevalence between age groups and the frequency of alleles (mutant and wild) in our study population. The lack of significant difference with age was also observed in a study by DJIMDE et al. 
The Prevalence of the Mutation According to Parasitaemia
Our results did not find any relationship between the Pfcrt76T mutation and the parasitaemia. Our results corroborate with those obtained by MAHAMAT et al., in (2008) , in Burkina Faso [16] . However, some literature reviews note that high parasite densities favour the appearance and selection of mutations under the influence of drug pressure [22] . This contradiction with ours could be explained by the fact that the test was carried by in vitro and giving only an overall response of the parasite population. 
Prevalence of pfcrt76T Mutation According to Study Areas
Our study showed that the Pfcrt76T mutation is a function of the study areas. Our results are different from those obtained by MAHAMAT et al., in (2008) , in the West (Dandé) and North (Gourcy) with Pfcrt76T respectively 48.8% and 50% in Burkina Faso [16] . This could be explained by the difference in epidemiological setting but mainly by the effect of the ACTs on the chloroquine-resistant parasites as the previous studies were conducted very close to the introduction of those news treatments. One additional explanation could also be the sample size for those previous studies used to characterize the mutation of the Pcrt76T gene, 47 samples, lower than that in our study. Also, the areas of Banfora and Saponé originate from two neighbouring epidemiological setting facies (equatorial stratum and tropical stratum) compared to that of Gourcy and Dandé (equatorial stratum and Sahelian stratum). However, our results corroborate with those obtained by HASTINGS and MACKINNON in the United Kingdom, in 1998 [23] and those generated by MOLYNEUX et al., in 1999 [24] .
The frequency of the Pfcrt76T mutation at Banfora and Saponé was 45.90% and 27.5%, respectively. It was previously argued that strong transmission may contribute to the emergence of resistant parasites strains in our study.
Influence of the Introduction of CTAs on the Prevalence of the Pfcrt76T Mutation
This study assessed the prevalence of the mutation associated with antimalarial resistance eight years after the introduction of CTAs in Burkina Faso. Indeed, the prevalence of Pfcrt 76T mutation before the introduction of CTAs was estimated at 60% in Burkina Faso [15] . With the studies conducted in 2008 and 2016, the overall results showed a prevalence of Pfcrt76T mutation at 50% [16] ; 24.78% [17] respectively; This was a representative of a decline in
Pfcrt76T mutation prevalence after a decade of the ACTs used in Burkina Faso as a proof of the efficacy against the chloroquine-resistant parasites [25] . Our study data are contributing as an additional confirmation of such reduction in Burkina Faso. However, the emergence of Plasmodium falciparum resistance to artemisinin derivatives as presented in Cambodia [7] , consists of a serious complexity in the control and elimination of malaria in the world. The spread of parasite resistance from Asia to Africa has already been well described previously with chloroquine and Sulfadoxine Pyrimethamine [9] . Then, this decrease in the sensitivity of Plasmodium to CTAs could jeopardize the progress in the fight against malaria.
CONCLUSION
This study showed a decrease in the prevalence of Pfcrt76T mutation about a few years after the introduction of Artemisinin-based Therapeutic Combinations in Burkina Faso. However, even the trends in the reduction of the chloroquineresistant parasite are effective and will result in the possible efficacy of chloroquine, the spread of the resistant parasite to artemisinin derivative may represent a very important threat for malaria treatment in Africa. Therefore, the monitoring of ACTs efficacy remains an important activity in Africa to delay the generalization of their resistance.
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